John Kirby Email

SVP and Chief Financial Officer . Idera Pharmaceuticals

Current Roles

Employees:
31
Revenue:
$7.5M
About
Idera Pharmaceuticals, Inc. (AMEX: IDP) is a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases. We have identified proprietary DNA-based structures that modulate TLR, which is one of the most promising new approaches in drug development. Our immune modulatory oligonucleotide (IMO™) compounds are broadly applicable to large and growing markets where significant unmet medical needs exist, including oncology, asthma/allergy, and infectious diseases. We continue to identify new drug candidates specific to various diseases, based on the differentiated biological activities of our IMO™ compounds. Our lead candidate is IMO-2055, a TLR9 agonist currently in phase 2 clinical testing for cancer. We also are collaborating with Novartis for the discovery, optimization, development, and commercialization of IMO™ drug candidates for the treatment of asthma and allergy indications.
Idera Pharmaceuticals Address
505 Eagleview Blvd
Lionville, PA
United States
Idera Pharmaceuticals Email

Past Companies

Idera PharmaceuticalsSenior Vice President and Chief Financial Officer
Idera PharmaceuticalsVice President, Finance
Idera PharmaceuticalsVice President, Corporate Accounting

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.